News und Analysen

The market may be close to all-time highs, but that has not prevented carnage from happening across many sectors. One stock that has recently been hit is SoFi Technologies (NASDAQ: SOFI). Down close

After years of lagging the market, has Pfizer (NYSE: PFE) finally found a spark? With unimpressive financial results and recent launches that have not generated enough sales to turn things around,

Vertex Pharmaceuticals (NASDAQ: VRTX) has significantly underperformed broader equities over the past 12 months, with its shares down 10% since March of 2025, compared to a 15% gain for the S&P 500.

The world for SoFi Technologies (NASDAQ: SOFI) just became messier. A famous short seller -- Muddy Waters Research -- released a report last week alleging that the fast-growing lender is engaging in

The independent research firm and short-seller, Muddy Waters Research, recently published a 28-page short report on the popular digital bank SoFi (NASDAQ: SOFI). SoFi pitches itself as a

Even the most dedicated income investors often avoid healthcare titles, especially those in the high-capital-expenditures pharmaceutical sector. As ever, though, we can find exceptions.

Here's a

Pfizer (NYSE: PFE) stock hasn't made for a good investment over the past five years. It has declined by 25% in value over that stretch, while the S&P 500 has climbed by 68%. Investors have lost

AbbVie (NYSE: ABBV) is a top healthcare stock, but it isn't trading like one of late. This year, it's down 11%, and it has been underperforming the S&P 500, which is down only 4%. Investors have

It's often wise to wait until a significant correction before investing in a stock. However, that strategy only works when the company can recover from whatever obstacle led to the sell-off. When

Explore the exciting world of Carlisle Companies (NYSE: CSL) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into

Over the past five years, CRISPR Therapeutics' (NASDAQ: CRSP) shares have significantly lagged broader equities. That's despite the company earning approval for its first commercialized medicine,

Equity markets have moved in the wrong direction over the past three weeks. They may not rebound and experience a sustained run from here on out. We are still dealing with a precarious global trade

Drug stocks can be somewhat volatile. Things like clinical setbacks or patent cliffs can sink their stock prices or erode their profits and market share. However, one good thing about companies in

Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) were both leaders in the coronavirus vaccine market. However, as sales of these products have declined significantly in recent years -- due to the

Eli Lilly (NYSE: LLY) and Vertex Pharmaceuticals (NASDAQ: VRTX) have several things in common. Both are among the more prominent drugmakers in the world, and both have delivered market-beating

Abbott Laboratories (NYSE: ABT), a medical device specialist, recently fell off a cliff after a disappointing quarterly update that missed consensus top-line estimates. The healthcare giant is

SoFi Technologies (NASDAQ:SOFI), a digital banking and lending platform, closed Wednesday at $17.18, down 1.09%. The stock moved as investors weighed SoFi’s rebuttal to Muddy Waters’ short report

It's not hard to find healthcare stocks, including small-cap biotech companies, trading below $50 per share. However, many of these are high-risk investments that are likely to destroy investors'

It's been a rough patch for UnitedHealth Group (NYSE: UNH) over the past couple of years. After its stock dropped by around 35% in 2025, it has continued to decline, down over 13% in 2026.

Despite

SoFi Technologies (NASDAQ:SOFI), an online personal finance platform, closed Tuesday at $17.37, down 1.47%. Shares moved lower after a new short-seller report alleged aggressive financial

Artificial intelligence (AI) has been the hottest thing on Wall Street over the past three years. Many believe the technology is here to stay and will make those who pick the right stocks

Pfizer (NYSE: PFE) has had its share of ups and downs in recent years. The pharma giant scored a major win in early pandemic days as it brought its coronavirus vaccine and later a coronavirus

Vertex Pharmaceuticals (NASDAQ: VRTX) has had a busy few years. The biotech company, known for its leadership in the cystic fibrosis (CF) treatment market, has proven its ability to broaden into

Over the past two years, Eli Lilly (NYSE: LLY) has established itself as the leader in the weight loss market. That's thanks to the company's tirzepatide, a compound sold under the brand name

Vertex Pharmaceuticals (NASDAQ: VRTX) has encountered several clinical setbacks over the past 18 months, including for two products in its growing pain medicine franchise. Even with recent approvals